Arcus Biosciences, Inc. (NYSE:RCUS) Shares Sold by Yousif Capital Management LLC

Yousif Capital Management LLC trimmed its position in Arcus Biosciences, Inc. (NYSE:RCUS) by 5.6% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 27,094 shares of the company’s stock after selling 1,605 shares during the period. Yousif Capital Management LLC’s holdings in Arcus Biosciences were worth $517,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also recently made changes to their positions in RCUS. BluePath Capital Management LLC acquired a new position in shares of Arcus Biosciences in the 3rd quarter valued at $28,000. GAMMA Investing LLC acquired a new position in shares of Arcus Biosciences in the 4th quarter valued at $31,000. Public Employees Retirement System of Ohio acquired a new position in shares of Arcus Biosciences in the 3rd quarter valued at $36,000. Strs Ohio purchased a new stake in shares of Arcus Biosciences during the 3rd quarter worth about $43,000. Finally, Exchange Traded Concepts LLC boosted its stake in shares of Arcus Biosciences by 34.0% during the 4th quarter. Exchange Traded Concepts LLC now owns 6,816 shares of the company’s stock worth $130,000 after acquiring an additional 1,729 shares in the last quarter. 92.89% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

RCUS has been the topic of several recent analyst reports. Wedbush reissued an “outperform” rating and set a $30.00 target price on shares of Arcus Biosciences in a research note on Thursday, February 22nd. Truist Financial reissued a “buy” rating and set a $50.00 target price on shares of Arcus Biosciences in a research note on Monday, March 25th. Finally, Mizuho decreased their price target on shares of Arcus Biosciences from $51.00 to $42.00 and set a “buy” rating on the stock in a research note on Tuesday, January 30th. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, Arcus Biosciences presently has an average rating of “Moderate Buy” and a consensus price target of $41.25.

Arcus Biosciences Trading Up 1.3 %

Shares of Arcus Biosciences stock opened at $15.70 on Monday. The firm has a market capitalization of $1.43 billion, a PE ratio of -3.78 and a beta of 0.91. Arcus Biosciences, Inc. has a twelve month low of $12.95 and a twelve month high of $25.47. The firm’s 50-day moving average price is $17.25 and its 200 day moving average price is $16.59.

Arcus Biosciences (NYSE:RCUS) last released its quarterly earnings data on Wednesday, February 21st. The company reported ($1.08) EPS for the quarter, beating analysts’ consensus estimates of ($1.09) by $0.01. The company had revenue of $31.00 million during the quarter, compared to the consensus estimate of $28.30 million. Arcus Biosciences had a negative net margin of 262.39% and a negative return on equity of 57.17%. Arcus Biosciences’s quarterly revenue was down 8.8% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.93) EPS. On average, sell-side analysts predict that Arcus Biosciences, Inc. will post -3.59 EPS for the current fiscal year.

Insider Buying and Selling at Arcus Biosciences

In other Arcus Biosciences news, COO Jennifer Jarrett sold 24,555 shares of the stock in a transaction dated Monday, February 26th. The shares were sold at an average price of $20.07, for a total value of $492,818.85. Following the completion of the sale, the chief operating officer now owns 274,323 shares in the company, valued at approximately $5,505,662.61. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other Arcus Biosciences news, President Juan C. Jaen sold 3,900 shares of the stock in a transaction dated Monday, February 26th. The shares were sold at an average price of $20.06, for a total value of $78,234.00. Following the completion of the sale, the president now owns 1,211,365 shares in the company, valued at approximately $24,299,981.90. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, COO Jennifer Jarrett sold 24,555 shares of the firm’s stock in a transaction that occurred on Monday, February 26th. The stock was sold at an average price of $20.07, for a total transaction of $492,818.85. Following the sale, the chief operating officer now owns 274,323 shares of the company’s stock, valued at approximately $5,505,662.61. The disclosure for this sale can be found here. In the last quarter, insiders sold 53,455 shares of company stock worth $1,014,779. Insiders own 13.80% of the company’s stock.

Arcus Biosciences Profile

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.